Nanomedicine : nanotechnology, biology, and medicine · 2026
Emerging nanocarrier platforms in Cervical cancer therapy: From Molecular targeting to Precision Nanomedicine.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Singh Samidha, Batra Naman, Mittal Saurabh
Аннотация
BACKGROUND: Cervical cancer being a significant global health burden, for which conventional treatments like surgery, chemotherapy, and radiotherapy are limited by poor tumour specificity, systemic toxicity, infertility, and compromised long-term disease control. These limitations highlight the need for advanced, targeted, and patient-friendly therapeutic strategies, nanocarrier-based drug delivery systems.
METHODS: This review evaluates recent advancements in nanocarrier platforms designed for cervical cancer therapy. A systematic analysis covering a wide spectrum of nanocarriers, solid lipid nanoparticles, dendrimers, carbon nanotubes, hydrogels, albumin-based nanoparticles, niosomes, surface-functionalized systems, and plant-derived vesicles. The review integrates findings from global preclinical and clinical studies, emphasizing drug-loading capacity, targeting efficiency, and therapeutic performance.
RESULT: Nanocarriers demonstrate enhanced tumour targeting via active, passive, and stimuli-responsive mechanisms. Their ability to co-deliver chemotherapeutics along with gene silencing agents, photothermal/magnetic functionalities, and tumour specific ligands, tend to enhance cellular uptake and help overcome multidrug resistance. Additionally, facilitating real-time monitoring and theranostic approach, integrating diagnosis and treatment.
CONCLUSION: Nanocarrier-based drug delivery offers a transformative pathway for cervical cancer management by providing safer, more effective, and personalised therapeutic options. Despite substantial progress, challenges such as large-scale manufacturing, in-vivo stability, long-term safety, and robust regulatory compliance must be addressed. Continued technological advancements and interdisciplinary coordination are expected to potentially benifit clinical translation and support precision medicine in cervical cancer care.
METHODS: This review evaluates recent advancements in nanocarrier platforms designed for cervical cancer therapy. A systematic analysis covering a wide spectrum of nanocarriers, solid lipid nanoparticles, dendrimers, carbon nanotubes, hydrogels, albumin-based nanoparticles, niosomes, surface-functionalized systems, and plant-derived vesicles. The review integrates findings from global preclinical and clinical studies, emphasizing drug-loading capacity, targeting efficiency, and therapeutic performance.
RESULT: Nanocarriers demonstrate enhanced tumour targeting via active, passive, and stimuli-responsive mechanisms. Their ability to co-deliver chemotherapeutics along with gene silencing agents, photothermal/magnetic functionalities, and tumour specific ligands, tend to enhance cellular uptake and help overcome multidrug resistance. Additionally, facilitating real-time monitoring and theranostic approach, integrating diagnosis and treatment.
CONCLUSION: Nanocarrier-based drug delivery offers a transformative pathway for cervical cancer management by providing safer, more effective, and personalised therapeutic options. Despite substantial progress, challenges such as large-scale manufacturing, in-vivo stability, long-term safety, and robust regulatory compliance must be addressed. Continued technological advancements and interdisciplinary coordination are expected to potentially benifit clinical translation and support precision medicine in cervical cancer care.